Research Study Opportunity

The purpose of clinical research is to explore new ways to improve health. With the help study participants, doctors can obtain the information needed to improve treatment options for future patients.

 

RAmP Registry for Amyloid Positive Patients

Avid Radiopharmaceuticals (Avid) is sponsoring a research registry to identify patients who have a positive PET scan result for amyloid plaque in the brain.

The goal of the registry is to identify patients who may be eligible for Eli Lilly and Company (Lilly) clinical trials for Alzheimer’s Disease. Participants who are potentially eligible for Lilly research opportunities will be matched with Clinical Trial Investigators in their geographical area.

Avid will use the results of the registry to find out whether such registries are beneficial for enrollment of Alzheimer’s Disease clinical trials.

 

Why is participation in research important?

There is currently no cure for Alzheimer’s Disease. Despite increasing numbers of people with the symptoms of Alzheimer’s Disease, enrollment in clinical trials to develop treatment for Alzheimer’s is low.

As the U.S. population age 65 and older continues to increase, the number of Americans with Alzheimer’s Disease and other dementias will grow. Researchers need volunteers for clinical trials in order to develop treatments that will benefit current and future patients.

 

Understanding your Participation

In order to participate, you must meet the following criteria:

  • Be at least 50 years of age
  • Have cognitive impairment with diagnosed or suspected Alzheimer’s disease
  • Have a positive amyloid PET scan. If you have not had a PET scan in the past, you must be willing to complete a scan as a part of the RAmP Registry Addendum.
    • Florbetapir F 18 PET Scan
      • A PET scan is a test that uses a radioactive compound to create an image of your brain. Increased amyloid plaques (a sticky buildup of a protein) in the brain have been linked with Alzheimer’s Disease and related brain disorders. A PET scan that is positive for amyloid plaque can help doctors determine if you have Alzheimer’s, especially if the disease is in the early stages. 
      • Researchers are interested in identifying patients who test positive for amyloid plaques as they may be good candidates for enrollment into clinical trials before their Alzheimer’s Disease progresses.
  • Have a study partner (Informant) who is willing to participate with you.
  • Be willing to be contacted for possible participation in Eli Lilly and Company (Lilly) clinical trials.
  • Provide written informed consent

 

What happens once I enroll in RAmP?

Once your eligibility in the registry is confirmed and you are enrolled, information on your medical history will be collected. You will also take tests of your memory and thinking that will be used to evaluate your eligibility for Lilly clinical trials.

After enrollment you will be contacted periodically so that your continued interest in participating in the registry can be confirmed. Participation will last 2 years.

If you are identified as a potential candidate for a Lilly clinical trial, you will be contacted and provided with the name of a participating investigator in your geographical area.

Being identified as a potential candidate does not guarantee that you will be eligible to participate. Eligibility for a clinical trial opportunity will be determined by the trial investigator.

 

If you are interested in participating in this opportunity, your doctor will provide you with additional details regarding the study. It is important that you understand the purpose and requirements of the study and that all of your questions are answered before you agree to participate. Before participating, you will be asked to provide written informed consent so that you may verify that you understand the requirements of the study.

Participation in RAmP will require that you share your personal contact and health information. Every effort will be made to protect your privacy and to keep your personal information confidential. Additional details regarding the protection of your personal information is described in the informed consent form.

You may withdraw your consent to participate in the registry at any time.


Additional Resources

For more information on Alzheimer’s Disease, please visit: